NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

Last week, the KPHC fell 2.2%, and the Danish healthcare stocks fell 5.7% due to a few stocks with large drawdowns. Both Curasight and Acarix enrolled the first patients in their clinical studies, while a board member of Genmab sold nearly MDKK 4 worth of shares, and DanCann Pharma was cut in half amidst their rights issue.

8 of the 22 Danish healthcare companies had a positive share price development the past week and 10 companies have had a positive share price performance year-to-date. Gubra is the best-performing Danish healthcare stock year-to-date with an 194% return and Redwood Pharma was the best Nordic healthcare investment last week.

---

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you invest more sustainably in the businesses of tomorrow.

---

DANISH COMPANY NEWS

Acarix

Acarix announces enrollment of first patient in US-based Clinical Workflow Evaluation Study (Link)

Ascendis Pharma

No news the past week

Biosergen

Biosergen receives the final permission required to test lead candidate BSG005 in patients with invasive fungal infection (Link)

Cessatech

No news the past week

CS Medica

CS MEDICA Announces Strategic Partnership with OneMed (Link)

Strategic Expansion through Innovation and Collaboration (Link)

Curasight

Curasight A/S resolves on directed issues and a loan facility (Link)

Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer (Link)

DanCann Pharma

Germany trends – prescriptions for medicinal cannabis positively influenced by new legalization (Link)

Submits applications for FLS03 and FLS04 to expand portfolio (Link)

The subscription period of DanCann Pharma’s Rights Issue begins today (Link)

Evaxion Biotech

No news the past week

ExpreS2ion

The subscription period in ExpreS2ion’s rights issue begins (Link)

Fluoguide

No news the past week

Genmab

A member of the board of directors sold shares worth nearly MDKK 4 (Link)

Gubra

No news the past week

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No news the past week

Saniona

No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week

ViroGates

No news the past week

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

No news the past week

2cureX

No news the past week

SELECTED CASES

SHARE PRICE DEVELOPMENTS – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a negative share price performance the past week of 5,7% compared to 2.2% for the KPHC index. Curasight became the best-performing Danish healthcare stock with a 33% increase following the enrollment of patients in a phase 2 trial leading to a milestone payment. The company also resolved on financing, which made the stock go even higher. Acarix rose 5% after they also announced the enrollment of the first patient in a clinical study. On the other hand, Genmab fell 6% after a board member sold nearly MDKK 4 worth of shares, and DanCann Pharma fell over 50% amidst their ongoing rights issue.

The best stock year-to-date is Gubra followed by Pila Pharma with 157-182% increases after the first 5.5 months of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 7.6%.

Overview of share price developments the past week, year-to-date, and last twelve months

NORDIC BIOTECH & HEALTHCARE DEVELOPMENTS

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell -2.2% to 65.91. The index has had a strong performance since the end of April, but last week the index took a hit. In the past 12 months, the KPHC index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 15%.

The index development for Kapital Partner Healthcare Index the past 12 months

194-65% in weekly return for the two best-performing Nordic biotech & healthcare stocks the past week

Redwood Pharma AB (194%)  focus is on the production of ophthalmic pharmaceuticals. The products contain active substances that are used in the treatment of dry eye disease (DED), characterised by dryness, pain, and burning. The disorder is caused by inflammation due to dysfunction of the glands as well as by the usage of contact lenses. The stock interestingly enough rose with any specific news at the time of the share price increase.

Duearity AB (65%) specializes in the development and production of technical solutions for the treatment and relief of tinnitus. The product portfolio includes, for example, the company’s proprietary products Tinearity and Duearity. In addition to the main business, service and associated ancillary services are also offered. 

Sources: Refinitiv Eikon, Cision, Nordnet & company websites